Featured Research

from universities, journals, and other organizations

Pathological complete response predictor of favorable breast cancer outcome

Date:
April 2, 2014
Source:
European Organisation for Research and Treatment of Cancer
Summary:
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer, a new trial demonstrates.

Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer.

Professor Hervι Bonnefoi of the Institut Bergoniι Comprehensive Cancer Centre in Bordeaux and coordinator of this study says, "An analysis such as the EORTC's was needed to consider breast cancer heterogeneity. Until recently, a link between pathological complete response and excellent prognosis had only been shown for some specific subtypes of breast cancer, e.g. triple negative and HER2-positive breast cancers, albeit with conflicting results. We wanted to see if the prognostic implications of pathological complete response, TP53 status, and the treatment administered (taxane or non-taxane) differed among breast cancer subtypes. We performed a landmark and two-step approach multivariate analyses to address these questions."

Patients in the intergroup EORTC 10994/BIG 1-00 phase III trial were randomized to receive either six cycles of anthracycline-based chemotherapy (non-taxane) or three cycles of docetaxel followed by three cycles of eprirubicin/docetaxel (taxane). Researchers used a landmark approach and a two-step multivariate analysis to study the potential effects of three interactions: breast cancer subtype and pathological complete response; breast cancer subtype and TP53 status; breast cancer subtype and treatment arm (i.e., taxane or non-taxane).

A patient was determined to have pathological complete response when no evidence was found of residual invasive cancer (or very few scattered tumor cells only) in the primary tumor and lymph nodes. According to this definition, pathological complete response was observed in 18% of the patients in this trial for whom sufficient data was available (1212 of the 1856 patients randomized).

In the univariate analyses there is no heterogeneity between the Hazard Ratios for pathological complete response in our study across the different subtypes. The prognostic effect of pathological complete response on event-free survival did not differ between breast cancer subtypes in a two-step multivariate analysis and was an independent predictor for better event-free survival (Hazard ratio (HR) = 0.40, P < 0.001 in favor of pathological complete response), distant metastasis-free survival (HR = 0.32, P < 0.001), and overall survival (HR = 0.32, P < 0.001). The findings have been confirmed in the recent FDA meta-analysis.

The treatment administered, i.e., taxane or non-taxane, was an independent predictor only for event-free survival and favored treatment with taxane (HR = 0.73, P = 0.004 ). The interaction between breast cancer subtype and TP53 only approached statistical significance for event-free survival (P = 0.1).


Story Source:

The above story is based on materials provided by European Organisation for Research and Treatment of Cancer. The original article was written by John Bean. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Bonnefoi, S. Litiere, M. Piccart, G. MacGrogan, P. Fumoleau, E. Brain, T. Petit, P. Rouanet, J. Jassem, C. Moldovan, A. Bodmer, K. Zaman, T. Cufer, M. Campone, E. Luporsi, P. Malmstrom, G. Werutsky, J. Bogaerts, J. Bergh, D. A. Cameron. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology, 2014; DOI: 10.1093/annonc/mdu118

Cite This Page:

European Organisation for Research and Treatment of Cancer. "Pathological complete response predictor of favorable breast cancer outcome." ScienceDaily. ScienceDaily, 2 April 2014. <www.sciencedaily.com/releases/2014/04/140402105740.htm>.
European Organisation for Research and Treatment of Cancer. (2014, April 2). Pathological complete response predictor of favorable breast cancer outcome. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2014/04/140402105740.htm
European Organisation for Research and Treatment of Cancer. "Pathological complete response predictor of favorable breast cancer outcome." ScienceDaily. www.sciencedaily.com/releases/2014/04/140402105740.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) — After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) — A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) — Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) — Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins